- Home
- PNTG vs GHRS Comparison
PNTG vs GHRS Comparison
Compare PNTG & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNTG
- GHRS
- Stock Information
- Founded
- PNTG 2019
- GHRS 2018
- Country
- PNTG United States
- GHRS Ireland
- Employees
- PNTG N/A
- GHRS N/A
- Industry
- PNTG Medical/Nursing Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- PNTG Health Care
- GHRS Health Care
- Exchange
- PNTG Nasdaq
- GHRS Nasdaq
- Market Cap
- PNTG 873.8M
- GHRS 753.0M
- IPO Year
- PNTG N/A
- GHRS 2021
- Fundamental
- Price
- PNTG $25.17
- GHRS $13.08
- Analyst Decision
- PNTG Buy
- GHRS Strong Buy
- Analyst Count
- PNTG 6
- GHRS 8
- Target Price
- PNTG $34.17
- GHRS $30.63
- AVG Volume (30 Days)
- PNTG 422.2K
- GHRS 254.5K
- Earning Date
- PNTG 08-06-2025
- GHRS 08-07-2025
- Dividend Yield
- PNTG N/A
- GHRS N/A
- EPS Growth
- PNTG 20.56
- GHRS N/A
- EPS
- PNTG 0.77
- GHRS N/A
- Revenue
- PNTG $798,923,000.00
- GHRS N/A
- Revenue This Year
- PNTG $25.01
- GHRS N/A
- Revenue Next Year
- PNTG $8.18
- GHRS N/A
- P/E Ratio
- PNTG $32.06
- GHRS N/A
- Revenue Growth
- PNTG 30.58
- GHRS N/A
- 52 Week Low
- PNTG $21.18
- GHRS $6.00
- 52 Week High
- PNTG $37.13
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- PNTG 53.03
- GHRS 47.54
- Support Level
- PNTG $24.73
- GHRS $11.32
- Resistance Level
- PNTG $27.16
- GHRS $13.15
- Average True Range (ATR)
- PNTG 1.03
- GHRS 0.73
- MACD
- PNTG 0.17
- GHRS 0.05
- Stochastic Oscillator
- PNTG 62.05
- GHRS 77.19
About PNTG The Pennant Group Inc.
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.